CSIMarket
 
Collegium Pharmaceutical Inc   (COLL)
Other Ticker:  
 
 
Price: $39.3500 $0.26 0.665%
Day's High: $39.9 Week Perf: 5.21 %
Day's Low: $ 38.86 30 Day Perf: 15.91 %
Volume (M): 580 52 Wk High: $ 39.90
Volume (M$): $ 22,815 52 Wk Avg: $25.82
Open: $39.39 52 Wk Low: $20.83



 Market Capitalization (Millions $) 1,469
 Shares Outstanding (Millions) 37
 Employees 253
 Revenues (TTM) (Millions $) 420
 Net Income (TTM) (Millions $) 48
 Cash Flow (TTM) (Millions $) 64
 Capital Exp. (TTM) (Millions $) 0

Collegium Pharmaceutical Inc
Collegium Pharmaceutical Inc is a publicly traded specialty pharmaceutical company based in Stoughton, Massachusetts. It was founded in 2002 by Michael Heffernan, who is the current CEO, and Joseph Ciaffoni, the current COO.

The company specializes in the development and commercialization of innovative treatments for chronic pain and other conditions. They work to address unmet medical needs by developing new treatments that are safer, more effective, and more accessible than the current standard of care.

One of Collegium's most successful products is Xtampza ER, an extended-release opioid medication for the treatment of chronic pain. Xtampza ER was approved by the FDA in 2016 and is designed to be harder to abuse than other opioids. It is also formulated to be tamper-resistant, which reduces the risk of addiction and overdose.

Collegium also offers an innovative drug delivery technology platform called DETERx. This technology allows medication to be released slowly over time, which helps to reduce the risk of abuse and addiction. DETERx is used in Xtampza ER and other Collegium products.

The company has a strong research and development pipeline, with several products in various stages of development. In addition to chronic pain, they are also exploring treatments for other conditions such as neuropathic pain and opioid use disorder.

Collegium is committed to patient-centered care and works to ensure that their products are safe, effective, and accessible to those who need them. They have a team of experienced professionals and a strong corporate culture that focuses on innovation, collaboration, and excellence.

Overall, Collegium Pharmaceutical Inc is a leading specialty pharmaceutical company that is dedicated to improving the lives of patients with chronic pain and other conditions. Their innovative products and drug delivery technologies are helping to reduce the risk of addiction and overdose, while providing effective relief to those who need it most.


   Company Address: 100 Technology Center Drive Stoughton 2072 MA
   Company Phone Number: 713-3699   Stock Exchange / Ticker: NASDAQ COLL
   


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Collegium Pharmaceutical Inc

Collegium Pharmaceutical Inc's Positive Momentum Overshadowed by Alarming Revenue Decline

Collegium Pharmaceutical Inc seems to be on a positive trajectory with their recent announcement of a $25 million Accelerated Share Repurchase program. However, despite this positive development, there are several concerning factors that investors should take into consideration.
First and foremost, while the company did achieve positive earnings of $0.58 per share in the October to December 31 2023 time-frame, it's important to note that this is only a marginal improvement from the previous financial reporting period. Additionally, the revenue for the same time-frame saw a dramatic decrease of -95.117% compared to the previous year. This significant drop in revenue raises red flags about the company's ability to generate consistent income and maintain profitability in the long run.

Contract

Collegium Pharmaceutical Announces $25 Million Accelerated Share Repurchase Program to Maximize Shareholder Value

Published Thu, Nov 9 2023 1:01 PM UTC

Collegium Announces $25 Million Accelerated Share Repurchase Program
Collegium Pharmaceutical, Inc., a renowned specialty pharmaceutical company dedicated to enhancing the lives of individuals grappling with severe medical conditions, disclosed on November 9, 2023, its plans to initiate a $25 million Accelerated Share Repurchase (ASR) program. In collaboration with Jeff...

Collegium Pharmaceutical Inc

Collegium Pharmaceutical Inc Skyrockets with Impressive 7.321% Revenue Growth in Q3 2023

In the third quarter of 2023, Collegium Pharmaceutical Inc experienced significant growth in revenue and earnings compared to the previous year. According to the company's financial report, revenue increased by 7.321% to $136.31 million, up from $127.01 million in the same quarter last year. Additionally, the company's earnings grew by an impressive 5200% to $0.53 per share, compared to $0.01 per share in the prior year quarter.
Collegium Pharmaceutical Inc's strong performance in revenue is notable, as it outperformed its industry peers who expressed a growth rate of only 1.86% during the same period. This indicates that the company has a competitive edge in the Major Pharmaceutical Preparations industry.

Collegium Pharmaceutical Inc

Collegium Pharmaceutical Inc Reports Profitability with $0.34 EPS in Q2 2023, Despite 30.764% Revenue Drop

Collegium Pharmaceutical Inc Sees Improved Profits and Margins, but Faces Revenue Decline
Collegium Pharmaceutical Inc, a major player in the pharmaceutical preparations industry, has reported positive financial results for the second quarter of 2023. The company's earnings per share (EPS) turned around from a loss of $0.15 per share in the same quarter a year prior to a profit of $0.34 per share. Additionally, the company's quarterly net income improved significantly, reaching $13.007 million compared to a net loss of $-5.191 million in the previous year.
One of the key highlights for Collegium Pharmaceutical Inc is its improving profit margins. The company's net margin rose to 9.65% in the April to June 30, 2023 interval, indicating a better ability to generate profits from its operations. Furthermore, its operating margin edged up to 26.43%. These positive trends suggest that the company is making efficient use of its resources and controlling costs effectively.

Collegium Pharmaceutical Inc

Collegium Pharmaceutical Inc. Reports Impressive 21.647% Revenue Increase in Recent Fiscal Period

Investors in the stock market are always on the lookout for promising companies that have the potential for growth and success. One such company that has caught the attention of many investors lately is Collegium Pharmaceutical Inc., a pharmaceutical company that has been recording some impressive revenue growth despite a net loss in the past fiscal period.
During the 12 months ending in the first quarter of 2023, Collegium Pharmaceutical Inc recorded a cumulative net loss of $-29 million, and the negative return on equity was -15.26%. However, it is important to note that within the major pharmaceutical preparations industry, there were 17 other companies that had a higher return on equity.






 

Collegium Pharmaceutical Inc's Segments
 
 
• View Complete Report
  Company Estimates  
  Revenue Outlook
Collegium Pharmaceutical Inc does not provide revenue guidance.

Earnings Outlook
Collegium Pharmaceutical Inc does not provide earnings estimates.

 
Geographic Revenue Dispersion




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com